Oncology Intelligence Digest July 14, 2026 The European Commission approved Merck KGaA’s Erbitux (cetuximab) in combination with encorafenib…
Oncology Intelligence Membership Required
You must be a Oncology Intelligence member to access this content.
Already a member? Log in here